On June 26, Hansoh Pharma's new Class 1 drug Hengmu® (Tenofovir Amibufenamide Tablets) started nationwide supply. Hengmu® is a new second-generation tenofovir independently developed by Hansoh Pharma, and also the first oral anti-hepatitis B virus (HBV) drug originally developed in China, for the treatment of adult patients with chronic hepatitis B. Compared with tenofovir disoproxil fumarate (TDF), Hengmu® requires less than one-tenth the dose to achieve similar antiviral efficacy, and delivers comparable antiviral efficacy as first-line drugs and better bone and kidney safety. The launch of Hengmu® will provide a new option for the treatment of hepatitis B in China.
▲ Hengmu® (Tenofovir Amibufenamide Tablets)
▲ Good news for hepatitis B patients; Hengmu® started nationwide supply
Hengmu® on the production line
▲ Strengthen lean management and provide whole-process drug quality and safety control to meet the medication requirements of hepatitis B patients with high quality
Hengmu® ready to go
▲ Race against time to accelerate accessibility and ensure supply; loading of Hengmu® is under way in an intense and orderly manner.
First shipment of Hengmu®
▲ In response to patients' expectations for a better tomorrow, boxes of Hengmu® are shipped to all parts of the country at full speed to protect patients' health with technological innovation.